"10.1371_journal.pone.0132702","plos one","2015-07-15T00:00:00Z","Annika Reddig; Mahsa Fatahi; Björn Friebe; Karina Guttek; Roland Hartig; Frank Godenschweger; Dirk Roggenbuck; Jens Ricke; Dirk Reinhold; Oliver Speck","Institute of Molecular and Clinical Immunology, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany; Department of Biomedical Magnetic Resonance, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany; Department of Radiology and Nuclear Medicine, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany; Medipan GmbH, Dahlewitz/Berlin, Germany; Faculty of Natural Sciences, Brandenburg University of Technology Cottbus-Senftenberg, Senftenberg, Germany; Leibniz Institute for Neurobiology, Magdeburg, Germany; Center for Behavioral Brain Sciences, Magdeburg, Germany; German Center for Neurodegenerative Disease, Magdeburg, Germany","Conceived and designed the experiments: AR MF BF JR D. Reinhold OS. Performed the experiments: AR MF BF KG RH FG. Analyzed the data: AR D. Roggenbuck D. Reinhold. Contributed reagents/materials/analysis tools: JR D. Roggenbuck D. Reinhold OS. Wrote the paper: AR MF BF.","The corresponding authors has read the journal's policy and the authors of this manuscript have the following competing interests: Dirk Roggenbuck is a shareholder of GA Generic Assays GmbH and Medipan GmbH, and is employed by Medipan GmbH. Both companies are diagnostic manufacturers. The remaining authors declare no conflict of interest. The Dept. of Biomedical Magnetic Resonance receives research support from Siemens Healthcare. This support, however, is not related to the subject of the current study. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.","2015","07","Annika Reddig","AR",10,TRUE,5,6,2,3,TRUE,TRUE,TRUE,1,"10",TRUE
